---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-125888"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:39:38.656767+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix prices $100.1M public offering; updates wet AMD trial and cash runway into 2027

## Summary
- Priced underwritten public offering of 30.8M shares at $3.25/share for gross proceeds of $100.1M; net proceeds ~$93.6M.
- Underwriters granted 30-day option for up to 4.62M additional shares; closing expected Dec 18, 2023.
- Submitted SPA amendment to FDA to broaden SOL trial inclusion criteria and test single 450 µg implant; patient enrollment may begin Jan 2024.
- Net proceeds plus existing cash expected to fund operations into 2027; additional capital needed for regulatory approval of AXPAXLI.

## SEC filing metadata
- accession: 0001104659-23-125888
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465923125888/0001104659-23-125888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465923125888/tm2332876d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-125888
- JSON: https://secwatch.observer/filing/0001104659-23-125888.json
- Plain text: https://secwatch.observer/filing/0001104659-23-125888.txt

## Key facts
- Material Agreements
  OCULAR THERAPEUTIX, INC entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters valued at public offering price of $3.25 per share (effective 2023-12-13).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters
  - Value: public offering price of $3.25 per share
  - Effective: 2023-12-13
  source text: On December 13, 2023, Ocular Therapeutix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 30,800,000 shares (the “Firm Shares”) of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465923125888/0001104659-23-125888-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.